Stem definition | Drug id | CAS RN |
---|---|---|
antibiotics, cefalosporanic acid derivatives | 535 | 88040-23-7 |
Dose | Unit | Route |
---|---|---|
4 | g | P |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 85 % | Benet LZ, Broccatelli F, Oprea TI |
BA (Bioavailability) | 99 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 0.28 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 2.20 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.78 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 1.90 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Jan. 18, 1996 | FDA | HOSPIRA INC |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Febrile neutropenia | 366.05 | 17.98 | 263 | 12987 | 94364 | 46578448 |
Encephalopathy | 273.66 | 17.98 | 150 | 13100 | 33439 | 46639373 |
Acute kidney injury | 259.60 | 17.98 | 326 | 12924 | 235529 | 46437283 |
Status epilepticus | 158.51 | 17.98 | 78 | 13172 | 13901 | 46658911 |
Sepsis | 147.49 | 17.98 | 187 | 13063 | 135827 | 46536985 |
Neurotoxicity | 145.06 | 17.98 | 73 | 13177 | 13644 | 46659168 |
Pyrexia | 138.82 | 17.98 | 305 | 12945 | 348497 | 46324315 |
Drug reaction with eosinophilia and systemic symptoms | 120.48 | 17.98 | 85 | 13165 | 29463 | 46643349 |
Cytokine release syndrome | 105.79 | 17.98 | 46 | 13204 | 6177 | 46666635 |
Tubulointerstitial nephritis | 101.26 | 17.98 | 59 | 13191 | 14729 | 46658083 |
Myoclonus | 97.58 | 17.98 | 57 | 13193 | 14295 | 46658517 |
Septic shock | 88.36 | 17.98 | 95 | 13155 | 57798 | 46615014 |
Thrombocytopenia | 80.02 | 17.98 | 135 | 13115 | 126446 | 46546366 |
Mental status changes | 77.39 | 17.98 | 73 | 13177 | 38015 | 46634797 |
Pneumonia | 71.94 | 17.98 | 252 | 12998 | 376068 | 46296744 |
Respiratory failure | 69.24 | 17.98 | 108 | 13142 | 94708 | 46578104 |
Multiple organ dysfunction syndrome | 67.13 | 17.98 | 78 | 13172 | 51632 | 46621180 |
Pain | 63.68 | 17.98 | 28 | 13222 | 476920 | 46195892 |
Arthralgia | 57.90 | 17.98 | 16 | 13234 | 364587 | 46308225 |
Pathogen resistance | 57.52 | 17.98 | 30 | 13220 | 6030 | 46666782 |
Neutrophil count decreased | 57.19 | 17.98 | 66 | 13184 | 43360 | 46629452 |
Renal tubular necrosis | 55.92 | 17.98 | 36 | 13214 | 10723 | 46662089 |
Klebsiella infection | 54.85 | 17.98 | 30 | 13220 | 6632 | 46666180 |
Fatigue | 53.06 | 17.98 | 57 | 13193 | 608640 | 46064172 |
Clostridium difficile colitis | 52.62 | 17.98 | 43 | 13207 | 18510 | 46654302 |
Platelet count decreased | 50.76 | 17.98 | 97 | 13153 | 99927 | 46572885 |
Rheumatoid arthritis | 50.26 | 17.98 | 5 | 13245 | 240210 | 46432602 |
Cytomegalovirus test positive | 48.43 | 17.98 | 21 | 13229 | 2799 | 46670013 |
Neutropenia | 46.52 | 17.98 | 116 | 13134 | 143088 | 46529724 |
Hypoxia | 46.38 | 17.98 | 65 | 13185 | 51773 | 46621039 |
Toxic encephalopathy | 45.03 | 17.98 | 24 | 13226 | 5038 | 46667774 |
Drug resistance | 44.58 | 17.98 | 38 | 13212 | 17330 | 46655482 |
Bacteraemia | 42.62 | 17.98 | 34 | 13216 | 14145 | 46658667 |
Confusional state | 41.31 | 17.98 | 119 | 13131 | 159773 | 46513039 |
Dizziness | 40.81 | 17.98 | 23 | 13227 | 340391 | 46332421 |
Nephropathy toxic | 38.88 | 17.98 | 25 | 13225 | 7429 | 46665383 |
Renal impairment | 38.79 | 17.98 | 73 | 13177 | 74299 | 46598513 |
Pancytopenia | 37.73 | 17.98 | 78 | 13172 | 84980 | 46587832 |
Malaise | 37.43 | 17.98 | 24 | 13226 | 331208 | 46341604 |
Headache | 36.10 | 17.98 | 50 | 13200 | 478302 | 46194510 |
Trichosporon infection | 34.70 | 17.98 | 9 | 13241 | 240 | 46672572 |
Clostridium difficile infection | 34.46 | 17.98 | 39 | 13211 | 25064 | 46647748 |
Product dose omission issue | 33.98 | 17.98 | 4 | 13246 | 168516 | 46504296 |
Nephritis allergic | 33.08 | 17.98 | 8 | 13242 | 159 | 46672653 |
Metabolic encephalopathy | 32.91 | 17.98 | 20 | 13230 | 5383 | 46667429 |
Alopecia | 32.38 | 17.98 | 4 | 13246 | 162410 | 46510402 |
Toxic epidermal necrolysis | 31.25 | 17.98 | 35 | 13215 | 22243 | 46650569 |
Cytomegalovirus viraemia | 30.99 | 17.98 | 18 | 13232 | 4460 | 46668352 |
Enterococcal bacteraemia | 30.81 | 17.98 | 12 | 13238 | 1217 | 46671595 |
Enterococcal infection | 30.56 | 17.98 | 21 | 13229 | 6966 | 46665846 |
Differentiation syndrome | 30.52 | 17.98 | 11 | 13239 | 900 | 46671912 |
Nasopharyngitis | 30.20 | 17.98 | 4 | 13246 | 153994 | 46518818 |
Aspartate aminotransferase increased | 30.12 | 17.98 | 68 | 13182 | 78632 | 46594180 |
Abdominal discomfort | 29.47 | 17.98 | 4 | 13246 | 151161 | 46521651 |
Blood creatinine increased | 29.22 | 17.98 | 66 | 13184 | 76337 | 46596475 |
Acute generalised exanthematous pustulosis | 29.22 | 17.98 | 23 | 13227 | 9382 | 46663430 |
Anaemia | 28.81 | 17.98 | 146 | 13104 | 255633 | 46417179 |
Respiratory distress | 28.50 | 17.98 | 40 | 13210 | 31876 | 46640936 |
Hypertensive heart disease | 28.06 | 17.98 | 14 | 13236 | 2564 | 46670248 |
Dysbiosis | 27.78 | 17.98 | 9 | 13241 | 533 | 46672279 |
Cholestatic liver injury | 27.73 | 17.98 | 13 | 13237 | 2077 | 46670735 |
Toxic skin eruption | 27.58 | 17.98 | 25 | 13225 | 12362 | 46660450 |
White blood cell count decreased | 27.49 | 17.98 | 82 | 13168 | 112149 | 46560663 |
Bronchopulmonary aspergillosis | 26.96 | 17.98 | 20 | 13230 | 7476 | 46665336 |
Graft versus host disease | 26.94 | 17.98 | 19 | 13231 | 6569 | 46666243 |
Hypotension | 26.35 | 17.98 | 133 | 13117 | 232456 | 46440356 |
Immune effector cell-associated neurotoxicity syndrome | 25.60 | 17.98 | 9 | 13241 | 685 | 46672127 |
Renal failure | 25.03 | 17.98 | 80 | 13170 | 113514 | 46559298 |
Acute respiratory distress syndrome | 25.03 | 17.98 | 31 | 13219 | 21891 | 46650921 |
Hyperoxaluria | 24.77 | 17.98 | 6 | 13244 | 120 | 46672692 |
Agranulocytosis | 24.73 | 17.98 | 31 | 13219 | 22154 | 46650658 |
Klebsiella bacteraemia | 24.34 | 17.98 | 10 | 13240 | 1166 | 46671646 |
Aphasia | 24.32 | 17.98 | 35 | 13215 | 28532 | 46644280 |
Weight decreased | 24.16 | 17.98 | 15 | 13235 | 210834 | 46461978 |
Drug intolerance | 24.15 | 17.98 | 6 | 13244 | 147043 | 46525769 |
Gait disturbance | 23.71 | 17.98 | 6 | 13244 | 145257 | 46527555 |
Acute graft versus host disease in skin | 23.37 | 17.98 | 13 | 13237 | 2969 | 46669843 |
Hyperbilirubinaemia | 23.10 | 17.98 | 21 | 13229 | 10417 | 46662395 |
Engraft failure | 22.50 | 17.98 | 7 | 13243 | 363 | 46672449 |
Chemotherapeutic drug level increased | 22.49 | 17.98 | 6 | 13244 | 179 | 46672633 |
Acute respiratory failure | 22.36 | 17.98 | 34 | 13216 | 29104 | 46643708 |
Respiratory alkalosis | 22.25 | 17.98 | 12 | 13238 | 2579 | 46670233 |
Fungaemia | 22.23 | 17.98 | 11 | 13239 | 1980 | 46670832 |
Hepatic function abnormal | 22.07 | 17.98 | 37 | 13213 | 34384 | 46638428 |
Disseminated intravascular coagulation | 21.90 | 17.98 | 27 | 13223 | 18978 | 46653834 |
Rash pustular | 21.64 | 17.98 | 17 | 13233 | 6912 | 46665900 |
Peripheral swelling | 21.45 | 17.98 | 9 | 13241 | 158062 | 46514750 |
Osteomyelitis | 21.41 | 17.98 | 29 | 13221 | 22354 | 46650458 |
Fall | 21.34 | 17.98 | 38 | 13212 | 329059 | 46343753 |
Antibiotic level above therapeutic | 20.94 | 17.98 | 6 | 13244 | 234 | 46672578 |
Electroencephalogram abnormal | 20.59 | 17.98 | 13 | 13237 | 3741 | 46669071 |
Muscle spasms | 20.25 | 17.98 | 5 | 13245 | 123108 | 46549704 |
Encephalitis Japanese B | 20.24 | 17.98 | 4 | 13246 | 29 | 46672783 |
Alanine aminotransferase increased | 20.13 | 17.98 | 63 | 13187 | 88388 | 46584424 |
Cholestasis | 20.10 | 17.98 | 31 | 13219 | 26862 | 46645950 |
Sinusitis | 19.98 | 17.98 | 6 | 13244 | 129762 | 46543050 |
Enterococcal sepsis | 19.86 | 17.98 | 9 | 13241 | 1331 | 46671481 |
Staphylococcal infection | 19.75 | 17.98 | 36 | 13214 | 35735 | 46637077 |
Depression | 19.62 | 17.98 | 12 | 13238 | 170092 | 46502720 |
Laryngeal inflammation | 19.43 | 17.98 | 5 | 13245 | 129 | 46672683 |
Rash maculo-papular | 19.27 | 17.98 | 31 | 13219 | 27843 | 46644969 |
Bone marrow failure | 19.16 | 17.98 | 32 | 13218 | 29637 | 46643175 |
Thrombotic microangiopathy | 18.95 | 17.98 | 17 | 13233 | 8289 | 46664523 |
Leukocytosis | 18.95 | 17.98 | 28 | 13222 | 23370 | 46649442 |
Electrocardiogram T wave alternans | 18.91 | 17.98 | 4 | 13246 | 42 | 46672770 |
Mucosal inflammation | 18.76 | 17.98 | 37 | 13213 | 38939 | 46633873 |
Lymphatic disorder | 18.76 | 17.98 | 6 | 13244 | 341 | 46672471 |
Tonsillitis bacterial | 18.71 | 17.98 | 5 | 13245 | 150 | 46672662 |
Drug-induced liver injury | 18.62 | 17.98 | 29 | 13221 | 25339 | 46647473 |
Tinea versicolour | 18.58 | 17.98 | 4 | 13246 | 46 | 46672766 |
Pseudomonas infection | 18.47 | 17.98 | 18 | 13232 | 9740 | 46663072 |
Factor V inhibition | 18.34 | 17.98 | 5 | 13245 | 162 | 46672650 |
Neutropenic colitis | 18.23 | 17.98 | 10 | 13240 | 2222 | 46670590 |
Serotonin syndrome | 18.22 | 17.98 | 28 | 13222 | 24192 | 46648620 |
Subdiaphragmatic abscess | 17.99 | 17.98 | 4 | 13246 | 54 | 46672758 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Febrile neutropenia | 253.32 | 15.70 | 312 | 17277 | 106381 | 29828508 |
Encephalopathy | 209.77 | 15.70 | 164 | 17425 | 32041 | 29902848 |
Acute kidney injury | 154.84 | 15.70 | 429 | 17160 | 273413 | 29661476 |
Neurotoxicity | 143.67 | 15.70 | 92 | 17497 | 13090 | 29921799 |
Cytokine release syndrome | 138.10 | 15.70 | 81 | 17508 | 9852 | 29925037 |
Septic shock | 107.64 | 15.70 | 158 | 17431 | 63449 | 29871440 |
Multiple organ dysfunction syndrome | 90.93 | 15.70 | 146 | 17443 | 63341 | 29871548 |
Pyrexia | 90.16 | 15.70 | 376 | 17213 | 294113 | 29640776 |
Respiratory failure | 89.13 | 15.70 | 188 | 17401 | 100454 | 29834435 |
Acute generalised exanthematous pustulosis | 80.23 | 15.70 | 48 | 17541 | 6050 | 29928839 |
Sepsis | 73.21 | 15.70 | 220 | 17369 | 146175 | 29788714 |
Myoclonus | 72.23 | 15.70 | 61 | 17528 | 13251 | 29921638 |
Renal tubular necrosis | 67.00 | 15.70 | 62 | 17527 | 15189 | 29919700 |
Fatigue | 62.49 | 15.70 | 58 | 17531 | 320615 | 29614274 |
Tubulointerstitial nephritis | 60.43 | 15.70 | 63 | 17526 | 17828 | 29917061 |
Hypoxia | 60.36 | 15.70 | 104 | 17485 | 47750 | 29887139 |
Neutrophil count decreased | 58.51 | 15.70 | 96 | 17493 | 42358 | 29892531 |
Enterococcal infection | 55.89 | 15.70 | 43 | 17546 | 8181 | 29926708 |
Mental status changes | 55.41 | 15.70 | 87 | 17502 | 36992 | 29897897 |
Neutropenia | 54.88 | 15.70 | 183 | 17406 | 128357 | 29806532 |
Clostridium difficile colitis | 52.42 | 15.70 | 50 | 17539 | 12718 | 29922171 |
Pathogen resistance | 50.75 | 15.70 | 41 | 17548 | 8369 | 29926520 |
Dizziness | 50.15 | 15.70 | 26 | 17563 | 194883 | 29740006 |
Status epilepticus | 46.68 | 15.70 | 44 | 17545 | 11028 | 29923861 |
Drug reaction with eosinophilia and systemic symptoms | 45.58 | 15.70 | 69 | 17520 | 28419 | 29906470 |
Meningitis candida | 43.53 | 15.70 | 10 | 17579 | 71 | 29934818 |
Brain herniation | 42.96 | 15.70 | 27 | 17562 | 3713 | 29931176 |
Product dose omission issue | 42.22 | 15.70 | 3 | 17586 | 91628 | 29843261 |
Myocardial infarction | 41.95 | 15.70 | 11 | 17578 | 125614 | 29809275 |
Disseminated intravascular coagulation | 41.73 | 15.70 | 58 | 17531 | 22113 | 29912776 |
Death | 41.54 | 15.70 | 93 | 17496 | 357190 | 29577699 |
Haemodialysis | 41.03 | 15.70 | 41 | 17548 | 11032 | 29923857 |
Bacteraemia | 37.53 | 15.70 | 46 | 17543 | 15514 | 29919375 |
Platelet count decreased | 37.44 | 15.70 | 142 | 17447 | 105987 | 29828902 |
Pseudomonas infection | 37.35 | 15.70 | 38 | 17551 | 10444 | 29924445 |
Methaemoglobinaemia | 36.27 | 15.70 | 21 | 17568 | 2489 | 29932400 |
Glomerulosclerosis | 36.16 | 15.70 | 14 | 17575 | 668 | 29934221 |
Botulism | 34.08 | 15.70 | 10 | 17579 | 200 | 29934689 |
Immune effector cell-associated neurotoxicity syndrome | 33.08 | 15.70 | 14 | 17575 | 842 | 29934047 |
Aspergillus infection | 32.76 | 15.70 | 35 | 17554 | 10179 | 29924710 |
White blood cell count decreased | 31.83 | 15.70 | 115 | 17474 | 83832 | 29851057 |
Fall | 31.80 | 15.70 | 36 | 17553 | 181836 | 29753053 |
Enterocolitis | 30.95 | 15.70 | 28 | 17561 | 6659 | 29928230 |
Cytomegalovirus enterocolitis | 30.03 | 15.70 | 13 | 17576 | 827 | 29934062 |
Blood culture positive | 29.72 | 15.70 | 24 | 17565 | 4895 | 29929994 |
Arthralgia | 29.51 | 15.70 | 22 | 17567 | 135769 | 29799120 |
Systemic candida | 29.37 | 15.70 | 19 | 17570 | 2745 | 29932144 |
Pneumonia | 28.78 | 15.70 | 311 | 17278 | 333995 | 29600894 |
Depression | 28.19 | 15.70 | 9 | 17580 | 90428 | 29844461 |
Metabolic encephalopathy | 28.15 | 15.70 | 21 | 17568 | 3814 | 29931075 |
Eosinophilia | 27.70 | 15.70 | 48 | 17541 | 22112 | 29912777 |
Bronchopulmonary aspergillosis | 27.51 | 15.70 | 35 | 17554 | 12249 | 29922640 |
Thrombocytopenia | 27.23 | 15.70 | 155 | 17434 | 136889 | 29798000 |
Pain | 27.20 | 15.70 | 37 | 17552 | 172604 | 29762285 |
Uraemic encephalopathy | 27.16 | 15.70 | 9 | 17580 | 272 | 29934617 |
Toxic encephalopathy | 26.82 | 15.70 | 22 | 17567 | 4587 | 29930302 |
Nephropathy toxic | 26.54 | 15.70 | 32 | 17557 | 10607 | 29924282 |
Pleural effusion | 26.01 | 15.70 | 99 | 17490 | 73967 | 29860922 |
Aspartate aminotransferase increased | 25.85 | 15.70 | 89 | 17500 | 63333 | 29871556 |
Antibiotic level above therapeutic | 24.89 | 15.70 | 8 | 17581 | 219 | 29934670 |
Fungal infection | 24.72 | 15.70 | 35 | 17554 | 13565 | 29921324 |
Transaminases increased | 24.49 | 15.70 | 47 | 17542 | 23410 | 29911479 |
Drug resistance | 24.37 | 15.70 | 43 | 17546 | 20090 | 29914799 |
Candida infection | 24.26 | 15.70 | 37 | 17552 | 15325 | 29919564 |
Malaise | 24.13 | 15.70 | 38 | 17551 | 166924 | 29767965 |
Cytokine storm | 24.07 | 15.70 | 10 | 17579 | 574 | 29934315 |
Red man syndrome | 23.75 | 15.70 | 11 | 17578 | 821 | 29934068 |
Clostridium difficile infection | 23.51 | 15.70 | 37 | 17552 | 15746 | 29919143 |
Confusional state | 23.26 | 15.70 | 147 | 17442 | 134687 | 29800202 |
Acute respiratory distress syndrome | 23.25 | 15.70 | 46 | 17543 | 23426 | 29911463 |
Insomnia | 23.15 | 15.70 | 13 | 17576 | 93323 | 29841566 |
Anxiety | 23.05 | 15.70 | 12 | 17577 | 89859 | 29845030 |
Cytomegalovirus viraemia | 22.69 | 15.70 | 22 | 17567 | 5707 | 29929182 |
Acute myeloid leukaemia recurrent | 22.47 | 15.70 | 13 | 17576 | 1539 | 29933350 |
Choluria | 22.46 | 15.70 | 7 | 17582 | 173 | 29934716 |
Gait disturbance | 22.33 | 15.70 | 8 | 17581 | 74769 | 29860120 |
Mucormycosis | 22.32 | 15.70 | 21 | 17568 | 5247 | 29929642 |
Dyspnoea | 21.97 | 15.70 | 111 | 17478 | 333184 | 29601705 |
Flavobacterium infection | 21.88 | 15.70 | 6 | 17583 | 93 | 29934796 |
Headache | 21.47 | 15.70 | 47 | 17542 | 182259 | 29752630 |
Pneumonia bacterial | 21.39 | 15.70 | 27 | 17562 | 9376 | 29925513 |
Kidney fibrosis | 21.34 | 15.70 | 14 | 17575 | 2071 | 29932818 |
Myelodysplastic syndrome | 21.32 | 15.70 | 39 | 17550 | 18739 | 29916150 |
Toxic epidermal necrolysis | 21.31 | 15.70 | 38 | 17551 | 17902 | 29916987 |
Peripheral swelling | 21.04 | 15.70 | 5 | 17584 | 61069 | 29873820 |
Blood pressure increased | 20.96 | 15.70 | 8 | 17581 | 71920 | 29862969 |
Immune thrombocytopenia | 20.87 | 15.70 | 24 | 17565 | 7567 | 29927322 |
Procalcitonin increased | 20.67 | 15.70 | 11 | 17578 | 1107 | 29933782 |
Septic embolus | 20.51 | 15.70 | 11 | 17578 | 1124 | 29933765 |
Aphasia | 20.35 | 15.70 | 39 | 17550 | 19400 | 29915489 |
Alanine aminotransferase increased | 20.35 | 15.70 | 92 | 17497 | 74184 | 29860705 |
Hypersensitivity vasculitis | 20.06 | 15.70 | 17 | 17572 | 3706 | 29931183 |
Asthenia | 20.04 | 15.70 | 65 | 17524 | 221225 | 29713664 |
Blood creatinine increased | 19.90 | 15.70 | 106 | 17483 | 91269 | 29843620 |
Trichosporon infection | 19.79 | 15.70 | 9 | 17580 | 644 | 29934245 |
Respiratory distress | 19.76 | 15.70 | 53 | 17536 | 32919 | 29901970 |
Staphylococcal sepsis | 19.63 | 15.70 | 26 | 17563 | 9465 | 29925424 |
Bacterial toxaemia | 19.62 | 15.70 | 6 | 17583 | 139 | 29934750 |
Aeromonas infection | 19.26 | 15.70 | 7 | 17582 | 280 | 29934609 |
Blastomycosis | 19.09 | 15.70 | 7 | 17582 | 287 | 29934602 |
Renal failure | 18.87 | 15.70 | 135 | 17454 | 128831 | 29806058 |
Feeling abnormal | 18.87 | 15.70 | 5 | 17584 | 56751 | 29878138 |
Pancytopenia | 18.75 | 15.70 | 99 | 17490 | 84953 | 29849936 |
Cerebral aspergillosis | 18.67 | 15.70 | 11 | 17578 | 1347 | 29933542 |
Pulmonary haemorrhage | 18.31 | 15.70 | 25 | 17564 | 9367 | 29925522 |
Eye infection fungal | 18.30 | 15.70 | 7 | 17582 | 323 | 29934566 |
Acute lymphocytic leukaemia recurrent | 18.24 | 15.70 | 14 | 17575 | 2653 | 29932236 |
Hypercapnia | 17.67 | 15.70 | 16 | 17573 | 3808 | 29931081 |
Retinal ischaemia | 17.49 | 15.70 | 7 | 17582 | 365 | 29934524 |
Intracranial mass | 17.38 | 15.70 | 10 | 17579 | 1171 | 29933718 |
Drug intolerance | 17.07 | 15.70 | 3 | 17586 | 45288 | 29889601 |
Drug level increased | 17.02 | 15.70 | 35 | 17554 | 18319 | 29916570 |
Cholestatic liver injury | 17.00 | 15.70 | 11 | 17578 | 1590 | 29933299 |
Dysbiosis | 16.93 | 15.70 | 7 | 17582 | 397 | 29934492 |
Cholestasis | 16.90 | 15.70 | 42 | 17547 | 24908 | 29909981 |
Weight decreased | 16.87 | 15.70 | 40 | 17549 | 150881 | 29784008 |
Rash morbilliform | 16.82 | 15.70 | 13 | 17576 | 2489 | 29932400 |
Hospitalisation | 16.56 | 15.70 | 3 | 17586 | 44316 | 29890573 |
Vanishing bile duct syndrome | 16.52 | 15.70 | 8 | 17581 | 660 | 29934229 |
Nasopharyngitis | 16.40 | 15.70 | 7 | 17582 | 58842 | 29876047 |
Unresponsive to stimuli | 16.37 | 15.70 | 43 | 17546 | 26376 | 29908513 |
Adenoviral haemorrhagic cystitis | 16.35 | 15.70 | 7 | 17582 | 433 | 29934456 |
Necrotising retinitis | 15.89 | 15.70 | 8 | 17581 | 717 | 29934172 |
Source | Code | Description |
---|---|---|
ATC | J01DE01 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Fourth-generation cephalosporins |
ATC | J01RA06 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE COMBINATIONS OF ANTIBACTERIALS Combinations of antibacterials |
FDA CS | M0003827 | Cephalosporins |
FDA EPC | N0000175488 | Cephalosporin Antibacterial |
MeSH PA | D000900 | Anti-Bacterial Agents |
MeSH PA | D000890 | Anti-Infective Agents |
CHEBI has role | CHEBI:36047 | antibacterial drugs |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Infection due to Pseudomonas aeruginosa | indication | 11218009 | |
Pneumonia due to Streptococcus | indication | 34020007 | |
Pneumonia due to Pseudomonas | indication | 41381004 | |
Bacterial pneumonia | indication | 53084003 | DOID:874 |
Klebsiella cystitis | indication | 60867007 | |
Infectious disease of abdomen | indication | 128070006 | |
Bacterial infection due to Klebsiella pneumoniae | indication | 186435004 | |
Bacterial peritonitis | indication | 197171003 | |
Pneumococcal pneumonia | indication | 233607000 | |
Escherichia coli urinary tract infection | indication | 301011002 | |
Proteus urinary tract infection | indication | 301012009 | |
Streptococcus pyogenes infection | indication | 302809008 | |
Bacterial urinary infection | indication | 312124009 | |
Infection due to Staphylococcus aureus | indication | 406602003 | |
Urinary tract infection caused by Klebsiella | indication | 369001000119100 | |
Complicated Proteus UTI | indication | ||
E. Coli Pyelonephritis | indication | ||
Complicated Urinary Tract Infections | indication | ||
Complicated Bacteroides Peritonitis | indication | ||
Complicated Streptococcus Peritonitis | indication | ||
Klebsiella Pyelonephritis | indication | ||
Complicated E. Coli Peritonitis | indication | ||
Enterobacter Pneumonia | indication | ||
Complicated Klebsiella Peritonitis | indication | ||
Proteus Pyelonephritis | indication | ||
Myoclonus | contraindication | 17450006 | |
Colitis | contraindication | 64226004 | DOID:0060180 |
Blood coagulation disorder | contraindication | 64779008 | DOID:1247 |
Factor II deficiency | contraindication | 73975000 | |
Disorder of brain | contraindication | 81308009 | DOID:936 |
Seizure disorder | contraindication | 128613002 | |
Impaired renal function disorder | contraindication | 197663003 | |
Pseudomembranous enterocolitis | contraindication | 397683000 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 2.32 | acidic |
pKa2 | 13.31 | acidic |
pKa3 | 3.1 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Bacterial penicillin-binding protein | Enzyme | INHIBITOR | CHEMBL | CHEMBL |
ID | Source |
---|---|
4024049 | VUID |
N0000022054 | NUI |
D01157 | KEGG_DRUG |
123171-59-5 | SECONDARY_CAS_RN |
4020908 | VANDF |
4024049 | VANDF |
C0055003 | UMLSCUI |
CHEBI:478164 | CHEBI |
9WT | PDB_CHEM_ID |
CHEMBL186 | ChEMBL_ID |
CHEMBL1200962 | ChEMBL_ID |
DB01413 | DRUGBANK_ID |
D000077723 | MESH_DESCRIPTOR_UI |
6092 | INN_ID |
2622 | PUBCHEM_CID |
10772 | IUPHAR_LIGAND_ID |
807PW4VQE3 | UNII |
20481 | RXNORM |
116681 | MMSL |
4373 | MMSL |
d03882 | MMSL |
004974 | NDDF |
004975 | NDDF |
370370003 | SNOMEDCT_US |
370371004 | SNOMEDCT_US |
96048006 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
CEFEPIME HYDROCHLORIDE AND DEXTROSE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0264-3193 | INJECTION, SOLUTION | 1 g | INTRAVENOUS | NDA | 29 sections |
CEFEPIME HYDROCHLORIDE AND DEXTROSE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0264-3195 | INJECTION, SOLUTION | 2 g | INTRAVENOUS | NDA | 29 sections |
Cefepime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0338-1301 | INJECTION, SOLUTION | 1 g | INTRAVENOUS | NDA | 28 sections |
Cefepime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-9566 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAVENOUS | ANDA | 27 sections |
Cefepime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-9735 | INJECTION, POWDER, FOR SOLUTION | 2 g | INTRAVENOUS | ANDA | 27 sections |
Cefepime Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-3222 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAVENOUS | ANDA | 27 sections |
Cefepime Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-3223 | INJECTION, POWDER, FOR SOLUTION | 2 g | INTRAVENOUS | ANDA | 27 sections |
cefepime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-121 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAVENOUS | ANDA | 30 sections |
cefepime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-121 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAVENOUS | ANDA | 30 sections |
cefepime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-122 | INJECTION, POWDER, FOR SOLUTION | 2 g | INTRAVENOUS | ANDA | 30 sections |
cefepime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-122 | INJECTION, POWDER, FOR SOLUTION | 2 g | INTRAVENOUS | ANDA | 30 sections |
Cefepime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 44567-130 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAVENOUS | ANDA | 27 sections |
Cefepime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 44567-131 | INJECTION, POWDER, FOR SOLUTION | 2 g | INTRAVENOUS | ANDA | 27 sections |
Cefepime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 44567-240 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAVENOUS | ANDA | 27 sections |
Cefepime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 44567-241 | INJECTION, POWDER, FOR SOLUTION | 2 g | INTRAVENOUS | ANDA | 27 sections |
Cefepime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60505-6144 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAVENOUS | ANDA | 28 sections |
Cefepime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60505-6145 | INJECTION, POWDER, FOR SOLUTION | 2 g | INTRAVENOUS | ANDA | 28 sections |
Cefepime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60505-6146 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAVENOUS | ANDA | 28 sections |
Cefepime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60505-6147 | INJECTION, POWDER, FOR SOLUTION | 2 g | INTRAVENOUS | ANDA | 28 sections |
Cefepime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-326 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAVENOUS | ANDA | 27 sections |
Cefepime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-340 | INJECTION, POWDER, FOR SOLUTION | 2 g | INTRAVENOUS | ANDA | 27 sections |
CEFEPIME | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66288-8100 | INJECTION, POWDER, FOR SOLUTION | 100 g | INTRAVENOUS | ANDA | 18 sections |
Cefepime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66794-209 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAMUSCULAR | ANDA | 17 sections |
Cefepime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66794-210 | INJECTION, POWDER, FOR SOLUTION | 2 g | INTRAMUSCULAR | ANDA | 17 sections |
Cefepime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67184-1002 | INJECTION, POWDER, FOR SOLUTION | 500 mg | INTRAVENOUS | ANDA | 28 sections |
Cefepime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67184-1003 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAVENOUS | ANDA | 28 sections |
Cefepime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67184-1004 | INJECTION, POWDER, FOR SOLUTION | 2 g | INTRAVENOUS | ANDA | 28 sections |
Cefepime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71288-008 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAVENOUS | ANDA | 30 sections |
Cefepime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71288-009 | INJECTION, POWDER, FOR SOLUTION | 2 g | INTRAVENOUS | ANDA | 30 sections |
Cefepime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71288-020 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAVENOUS | ANDA | 30 sections |